NCT06670352View on ClinicalTrials.gov

Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 12, 2024

Primary Completion Date

November 23, 2025

Study Completion Date

March 15, 2026

Conditions
IgA Nephropathy (IgAN)
Interventions
DRUG

Placebo

QD or BID, 24-weeks fixed dose.

DRUG

HSK39297 50mgBID

24-weeks fixed dose.

DRUG

HSK39297 100mgBID

24-weeks fixed dose.

DRUG

HSK39297 200mgQD

24-weeks fixed dose.

Trial Locations (2)

100034

RECRUITING

Peking University First Hospital, Beijing

210000

RECRUITING

Nanjing Drum Tower Hospital, Nanjing

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY